Kyle Gilmour
Tameside Hospital
6 Papers
3 Citations
Kyle Gilmour is an academic researcher from Tameside Hospital. The author has contributed to research in topics: Endometrial cancer & Metformin. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial.
Nicola Cherry,Kyle Gilmour,Philip C Hannaford,Anthony M. Heagerty,Mohammed Khan,Henry C Kitchener,Roseanne McNamee,Max Elstein,Clifford R. Kay,Mourad W. Seif,Hilary Buckley,Esprit team +11 more
TL;DR: Oestradiol valerate does not reduce the overall risk of further cardiac events in postmenopausal women who have survived a myocardial infarction, and all-cause mortality was not significant.
356
PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
Sarah Kitson,Zoe Maskell,Vanitha N Sivalingam,Jennifer L. Allen,S Ali,S Ali,Sean Burns,Kyle Gilmour,Rahamatulla Latheef,Richard J Slade,Philip W. Pemberton,Joseph Shaw,W David J Ryder,Henry C Kitchener,Emma J Crosbie,Emma J Crosbie +15 more
TL;DR: Short-term treatment with standard diabetic doses of metformin does not reduce tumor proliferation in women with endometrioid endometrial cancer awaiting hysterectomy and casts doubt on its potential application in the primary and adjuvant treatment settings.
Pre-surgical window study of metformin in obesity-driven endometrial cancer
Vanitha N Sivalingam,Rhona J McVey,Sarah Kitson,Kyle Gilmour,S Ali,Chris Roberts,Andrew G Renehan,Henry C Kitchener,Emma J Crosbie +8 more
TL;DR: RNA sequencing analysis of treated and untreated PDX tumors demonstrated that numerous factors with roles in ribosomal synthesis were significantly altered by treatment, offering a novel opportunity to specifically target the chemoresistant population in ovarian cancer.
4
Pre-Surgical Metformin in Uterine Malignancy (Premium): A Multi-Centre, Randomised Double-Blind, Placebo-Controlled Phase 3 Trial
Sarah Kitson,Zoe Maskell,Vanitha N Sivalingam,Jennifer L. Allen,Saad Ali,Saad Ali,Sean Burns,Kyle Gilmour,Rahamatulla Latheef,Richard J Slade,Phil Pemberton,Joseph Shaw,W David J Ryder,Henry C Kitchener,Henry C Kitchener,Emma J Crosbie +15 more
TL;DR: This paper showed that short-term treatment with standard diabetic doses of metformin does not reduce tumour proliferation in women with endometrial cancer awaiting hysterectomy and cast doubt on its potential application in the primary and adjuvant treatment settings.
2
A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer
Vanitha N Sivalingam,Rhona J McVey,Kyle Gilmour,S Ali,Chris Roberts,Andrew G Renehan,Henry C Kitchener,Emma J Crosbie +7 more
TL;DR: The hypothesis that metformin would reduce cellular proliferation in vivo in atypical endometrial hyperplasia and endometrioid adenocarcinoma by inducing phosphorylation of AMP-activated kinase and subsequent mTOR proproliferative inhibition, independent of insulin and insulin-like growth factor receptor activation is explored.